ETHY-001 targets the causal pathogenic mechanism underlying both conditions –– Patient-friendly subcutaneous administration with half-life ...
Ethyreal Bio has exited stealth with $101 million, joining the queue of companies preparing to challenge Amgen’s Tepezza.
CAMBRIDGE, Mass., June 10, 2026 (GLOBE NEWSWIRE) -- Ethyreal Bio ("Ethyreal” or "the Company”), a biotechnology company developing precision therapies for thyroid diseases with high unmet need, ...
The startup is developing a medicine that works differently than available treatments for thyroid eye disease and could ...
San Francisco-based SonoThera closed an oversubscribed $125 million Series B financing round, saying it will use the proceeds ...
Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 9, 2026 4:00 PM EDTCompany ParticipantsStephen Mahoney ...
On June 1, 2026, Biohaven Ltd. (NYSE:BHVN) announced the initiation of first-in-human dosing for BHV-8100, its oral, ...
The formation of supramolecular structures (dimers or oligomers) is emerging as an important aspect of G-protein-coupled receptor (GPCR) biology. In some cases, GPCR oligomerization is a prerequisite ...
– Backed by leading healthcare investors including Atlas Venture, Medicxi Ventures, Avoro Capital, Nandi Life Sciences, and Checkpoint Capital – CAMBRIDGE, Mass., June 10, 2026 (GLOBE NEWSWIRE) -- ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results